BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 10:30:00 AM | Browse: 1539 | Download: 1298
 |
Received |
|
2013-05-03 10:36 |
 |
Peer-Review Started |
|
2013-05-03 16:27 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-05-20 09:16 |
 |
Revised |
|
2013-06-05 18:54 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-07-05 11:56 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-07-05 13:06 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
2013-07-11 03:31 |
 |
Typeset the Manuscript |
|
2013-09-10 10:53 |
 |
Publish the Manuscript Online |
|
2013-10-31 15:14 |
| Category |
Oncology |
| Manuscript Type |
Autobiography |
| Article Title |
Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Keishiro Aoyagi, Kikuo Kouhuji, Motoshi Miyagi, Junya Kizaki, Taro Isobe, Kousuke Hashimoto and Kazuo Shirouzu |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Keishiro Aoyagi, Assistant Professor, Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan. keishiro@med.kurume-u.ac.jp |
| Key Words |
Gastric cancer; Peritoneal metastasis; Vascular endothelial growth factor; MKN-45P; Bevacizumab |
| Core Tip |
|
| Publish Date |
2013-10-31 15:14 |
| Citation |
Aoyagi K, Kouhuji K, Miyagi M, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer. World J Crit Care Med 2013; 2(4): 48-55 |
| URL |
http://www.wjgnet.com/2220-3141/full/v2/i4/48.htm |
| DOI |
http://dx.doi.org/10.5492/wjccm.v2.i4.48 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.